Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Multicenter Open-label Dose-escalation Study of Safety, Tolerability, PK/PD and Immunogenicity of Single/Multiple Subcutaneous PL54 Injection in Adult PKU Patients

NCT07672756 is registered in ClinicalTrials.gov with Chongqing Peg-Bio Biopharm Co., Ltd. as lead sponsor.

NCT NCT07672756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07672756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Multicenter Open-label Dose-escalation Study of Safety, Tolerability, PK/PD and Immunogenicity of Single/Multiple Subcutaneous PL54 Injection in Adult PKU Patients
Lead sponsor
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 20, 2025
Completion date
August 1, 2027
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonuria (pku)